▶ A webinar on the topic of 'Clinical Utility of NT-proBNP Cardia Biomarker in Diagnosis' was held on the 1st of December▶ Part two in the webinar series is planned for the 20th of December on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'The speaker of this webinar, Dr. Geri Lake-Bakaar, introduced Cardiac Biomarkers (NT-proBNP) which are greatly useful in the diagnosis of heart disease and evaluate patients' prognosis in dogs and cats.Dr. Geri Lake-Bakaar is an alumnus of Harvard and Cornell University and in 2013, she became a Board-certified veterinary specialist in Cardiology (DACVIM, Cardiology) from UC Davis. NT-proBNP can be used to screen for Occult Cardiomyopathy which doesn't have any clinical symptoms and especially be useful as a preanesthetic test or when the patient displays heart murmurs. Further, it can also be useful in determining whether the respiratory symptoms of the patient are caused by congestive heart failure or respiratory diseases.Increased levels of NT-proBNP in patients with heart disease are associated with impending heart failure, with a high probability of progressing to congestive heart failure in dogs above 1,500 pmol/L. In humans, NT-proBNP markers are also utilized clinically, and when the value decreases by more than 30%, the clinical prognosis can be determined to be good. On the other hand, when there is no change in the value or if there is an increase, it can be considered as an indicator of bad prognosis. However, the increased NT-proBNP levels could be due to heart failure, ischemia, and arrhythmia as well, so caution was advised in interpreting the results. In the case of commercially available qualitative measurement kits for feline NT-proBNP, while they can be used to exclude heart disease from the diagnostic differentials, it was emphasized that the results of quantitative tests should be used together with the qualitative results because false positives are common in quantitative tests. On the other hand, the NT-proBNP kit from BIONOTE Inc., which provides accurate quantitative results on-site in just a couple of minutes using the Vcheck equipment, was mentioned as a clinically useful method for diagnosis by Dr. Lake-Bakaar. On Wednesday the 20th of December, Dr. Lake-Bakaar will hold the second part of the cardiac biomarker webinar series, specifically on the topic of 'Point-of-Care NT-proBNP in Diagnosis and Management of Cardiac Disease'. In this webinar, she will provide more detailed information on how NT-proBNP levels are useful in monitoring treatment plans in hospitalized patients of patients receiving outpatient treatments.The webinar is free for anyone to join through the QR code and will start at 10 am Korean Standard Time (KST).
▶ Presented on the topic of molecular diagnostics market trends and changes in POC PCR equipment technology▶ Announced plans to accelerate global business by expanding reagent parameters of Vcheck M10 amid expanding veterinary molecular diagnostics marketGlobal leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced on the 8th of December, that they presented on the topic of POC PCR (Pointe of Care Polymerase Chain Reaction) at the 2023 Korean Society of Veterinary Science Fall Academic Conference, held at the Jeju International Convention Center on the 29th of November to 2nd of December. At this year's conference, a total of 19 academic sessions were held under the theme of "Advanced Fusion and Technology of Veterinary Biomedical Research". BIONOTE's resident DVM, Dr. Angela Moon, presented at the "Field Application fo Advanced Molecular Diagnostic Technology for Animal Diseases" session of Symposium 13, on the topic of "Point of Care Testing Application Trends of PCR In Companion Animal Disease Diagnosis". The primary focus was on the market trends of molecular diagnostics in the global veterinary market and changes in Point of Care PCR equipment technology. The global veterinary molecular diagnostics market size is expected to grow from 300 billion KRW in 2021 to 540 billion KRW by 2026, with an average annual growth of 10%. In addition, 95% of all PCR tests are currently referred to diagnostic laboratories, and only about 5% are carried out using POC equipment. However, as improved POC PCR equipment continues to be developed, a significant change in the market share is expected within the next 5 years. Vcheck M10, launched by BIONOTE in the second half of last year, is a Real-time PCR device that performs nucleic acid extraction, amplification, and results analysis all within an hour using a single device. It is also characterized by the ability to scale up depending on the needs of the customer, from specialized laboratories to small and large vet clinics, through the expansion of up to 8 channels. A BIONOTE spokesperson stated, " We plan on continuing to expand the reagent parameters to accelerate our global business growth" and "We are also planning to launch our Babesia gibsoni cartridge and enter the domestic market after acquiring the necessary regulatory clearance".
▶ Attended the Congreso Veterinario de León, held in Mexico for 4 days between the 6th and 9th of September▶ Intends to continue to increase supply and service towards end-users... continue to increase M/S in Latin America Global leader in Veterinary Diagnostics and Biological Raw Materials BIONOTE Inc., announced today that they participated in Congreso Veterinario de León (CVDL), the largest veterinary conference in Latin America.The Conference was held in León, Mexico for 4 days between the 6th and 9th of September.CVDL is the largest veterinary conference in Latin America, held every year in León Mexico since 1995. This conference is a gathering of over 900 veterinary companies from all over South and Central Americas, including Mexico, as well as veterinarians from around the World, with over 30 academic seminars. Through this conference, BIONOTE was able to promote their rapid diagnostic tests (RDTs), fluorescent immunoassay platform Vcheck F, Point of Care (POC) molecular diagnostic platform Vcheck M as well as the soon to be launched Vcheck C, the versatile high-throughput chemistry analyzer. Furthermore, BIONOTE was able to receive valuable feedback and insight regarding their current products from the veterinarian end-users, as well as have meaningful discussions with BIONOTE's Latin American dealers regarding future plans and strategies to increase M/S & to successfuly launch the newest products. A BIONOTE spokesperson commented that "the Latin American market is rapidly expanding" and that "BIONOTE will continue to not only provide excellent quality products, but to also provide the necessary training, academic support and services for the customers in order to strengthen our position in the Latin American market while increasing M/S".